Four-drug sequential regimen in advanced breast cancer

Laura Ferrari, Emilio Bajetta, Luca Gianni, Claudio Verusio, Cesare Bartoli, Pinuccia Valagussa, Gianni Bonadonna

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The results of two empirically designed and potentially non-cross-resistant combinations administered sequentially in advanced breast cancer with the intent of achieving a high rate of durable complete remissions were analyzed. The two drug combinations consisted of cyclophosphamide plus Adriamycin and high-dose methotrexate plus cisplatin given for a total of three cycles; twenty evaluable patients, not previously treated with chemotherapy, were entered into the study. Ten patients were allocated to receive cyclophosphamide and Adriamycin first followed by high-dose methotrexate and cisplatin, while the remaining patients received the opposite sequence. The overall response rate for the entire group was 85% (17 of 20). However, only three of 20 (15%) patients achieved complete remission. One additional complete response was observed when treatment was prolonged for an additional complete cycle. The overall median duration of response was 13 months (range, 5-20+ months). Responses were similarly distributed among different sites of lesions. Myelosuppression and gastrointestinal toxicity were mild and transient. Reversible acute renal failure was observed after methotrexate administration in three cases. Present results indicate that overall this sequential treatment appears effective in patients with advanced breast cancer. However, the lack of an increased complete remission rate over conventional regimens coupled with a potential risk of renal toxicity prevents further studies with this multiple drug combination.

Original languageEnglish
Pages (from-to)151-157
Number of pages7
JournalBreast Cancer Research and Treatment
Volume10
Issue number2
DOIs
Publication statusPublished - Nov 1987

Fingerprint

Breast Neoplasms
Methotrexate
Pharmaceutical Preparations
Drug Combinations
Doxorubicin
Cyclophosphamide
Cisplatin
Acute Kidney Injury
Kidney
Drug Therapy
Therapeutics

Keywords

  • advanced breast cancer
  • cyclophosphamide plus Adriamycin
  • high-dose methotrexate plus cisplatin
  • sequential chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ferrari, L., Bajetta, E., Gianni, L., Verusio, C., Bartoli, C., Valagussa, P., & Bonadonna, G. (1987). Four-drug sequential regimen in advanced breast cancer. Breast Cancer Research and Treatment, 10(2), 151-157. https://doi.org/10.1007/BF01810578

Four-drug sequential regimen in advanced breast cancer. / Ferrari, Laura; Bajetta, Emilio; Gianni, Luca; Verusio, Claudio; Bartoli, Cesare; Valagussa, Pinuccia; Bonadonna, Gianni.

In: Breast Cancer Research and Treatment, Vol. 10, No. 2, 11.1987, p. 151-157.

Research output: Contribution to journalArticle

Ferrari, L, Bajetta, E, Gianni, L, Verusio, C, Bartoli, C, Valagussa, P & Bonadonna, G 1987, 'Four-drug sequential regimen in advanced breast cancer', Breast Cancer Research and Treatment, vol. 10, no. 2, pp. 151-157. https://doi.org/10.1007/BF01810578
Ferrari, Laura ; Bajetta, Emilio ; Gianni, Luca ; Verusio, Claudio ; Bartoli, Cesare ; Valagussa, Pinuccia ; Bonadonna, Gianni. / Four-drug sequential regimen in advanced breast cancer. In: Breast Cancer Research and Treatment. 1987 ; Vol. 10, No. 2. pp. 151-157.
@article{b64ee06fe2da4ec5af3170f1e1f8c70b,
title = "Four-drug sequential regimen in advanced breast cancer",
abstract = "The results of two empirically designed and potentially non-cross-resistant combinations administered sequentially in advanced breast cancer with the intent of achieving a high rate of durable complete remissions were analyzed. The two drug combinations consisted of cyclophosphamide plus Adriamycin and high-dose methotrexate plus cisplatin given for a total of three cycles; twenty evaluable patients, not previously treated with chemotherapy, were entered into the study. Ten patients were allocated to receive cyclophosphamide and Adriamycin first followed by high-dose methotrexate and cisplatin, while the remaining patients received the opposite sequence. The overall response rate for the entire group was 85{\%} (17 of 20). However, only three of 20 (15{\%}) patients achieved complete remission. One additional complete response was observed when treatment was prolonged for an additional complete cycle. The overall median duration of response was 13 months (range, 5-20+ months). Responses were similarly distributed among different sites of lesions. Myelosuppression and gastrointestinal toxicity were mild and transient. Reversible acute renal failure was observed after methotrexate administration in three cases. Present results indicate that overall this sequential treatment appears effective in patients with advanced breast cancer. However, the lack of an increased complete remission rate over conventional regimens coupled with a potential risk of renal toxicity prevents further studies with this multiple drug combination.",
keywords = "advanced breast cancer, cyclophosphamide plus Adriamycin, high-dose methotrexate plus cisplatin, sequential chemotherapy",
author = "Laura Ferrari and Emilio Bajetta and Luca Gianni and Claudio Verusio and Cesare Bartoli and Pinuccia Valagussa and Gianni Bonadonna",
year = "1987",
month = "11",
doi = "10.1007/BF01810578",
language = "English",
volume = "10",
pages = "151--157",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "2",

}

TY - JOUR

T1 - Four-drug sequential regimen in advanced breast cancer

AU - Ferrari, Laura

AU - Bajetta, Emilio

AU - Gianni, Luca

AU - Verusio, Claudio

AU - Bartoli, Cesare

AU - Valagussa, Pinuccia

AU - Bonadonna, Gianni

PY - 1987/11

Y1 - 1987/11

N2 - The results of two empirically designed and potentially non-cross-resistant combinations administered sequentially in advanced breast cancer with the intent of achieving a high rate of durable complete remissions were analyzed. The two drug combinations consisted of cyclophosphamide plus Adriamycin and high-dose methotrexate plus cisplatin given for a total of three cycles; twenty evaluable patients, not previously treated with chemotherapy, were entered into the study. Ten patients were allocated to receive cyclophosphamide and Adriamycin first followed by high-dose methotrexate and cisplatin, while the remaining patients received the opposite sequence. The overall response rate for the entire group was 85% (17 of 20). However, only three of 20 (15%) patients achieved complete remission. One additional complete response was observed when treatment was prolonged for an additional complete cycle. The overall median duration of response was 13 months (range, 5-20+ months). Responses were similarly distributed among different sites of lesions. Myelosuppression and gastrointestinal toxicity were mild and transient. Reversible acute renal failure was observed after methotrexate administration in three cases. Present results indicate that overall this sequential treatment appears effective in patients with advanced breast cancer. However, the lack of an increased complete remission rate over conventional regimens coupled with a potential risk of renal toxicity prevents further studies with this multiple drug combination.

AB - The results of two empirically designed and potentially non-cross-resistant combinations administered sequentially in advanced breast cancer with the intent of achieving a high rate of durable complete remissions were analyzed. The two drug combinations consisted of cyclophosphamide plus Adriamycin and high-dose methotrexate plus cisplatin given for a total of three cycles; twenty evaluable patients, not previously treated with chemotherapy, were entered into the study. Ten patients were allocated to receive cyclophosphamide and Adriamycin first followed by high-dose methotrexate and cisplatin, while the remaining patients received the opposite sequence. The overall response rate for the entire group was 85% (17 of 20). However, only three of 20 (15%) patients achieved complete remission. One additional complete response was observed when treatment was prolonged for an additional complete cycle. The overall median duration of response was 13 months (range, 5-20+ months). Responses were similarly distributed among different sites of lesions. Myelosuppression and gastrointestinal toxicity were mild and transient. Reversible acute renal failure was observed after methotrexate administration in three cases. Present results indicate that overall this sequential treatment appears effective in patients with advanced breast cancer. However, the lack of an increased complete remission rate over conventional regimens coupled with a potential risk of renal toxicity prevents further studies with this multiple drug combination.

KW - advanced breast cancer

KW - cyclophosphamide plus Adriamycin

KW - high-dose methotrexate plus cisplatin

KW - sequential chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0023546933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023546933&partnerID=8YFLogxK

U2 - 10.1007/BF01810578

DO - 10.1007/BF01810578

M3 - Article

VL - 10

SP - 151

EP - 157

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -